PNV Media Thread, page-14

Article about Establishment Lab's recent IPO and listing on Nasdaq  (ESTA)

https://www.forbes.com/sites/moirav...-to-go-public-on-a-u-s-exchange/#2f9da6224640

The bit I really like is extracted below

Much of their innovation has revolved around creating a cell-friendly surface on breast implants. As Chacón-Quirós describes it, previous methods for manufacturing breast implants relied on secondary processes that introduced additional materials into the surface that can create friction, abrasions and difficulties in healing for patients.
By innovating a production method using nanotechnology and 3D printers to create an exacting surface, Establishment Labs claims to have produced a more biocompatible product, that improves safety and outcomes and has been widely embraced by plastic surgeons around the world.
As they enter the quiet period between a very big day and their first public report of earnings, there is a satisfaction to the silence.
Establishment Labs will use proceeds from the IPO to afford and navigate the FDA clinical trial process. Although they’ve been at work on the paperwork for some time, with today’s IPO, they begin their work in earnest to become the most innovative breast implant and reconstructive product available in the U.S. market.